Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2021
World first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio (inclisiran)
1 September 2021 - Agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management ...
Posted by Michael Wonder on 27 Aug 2021
NICE ‘no’ for Janssen’s Darzalex combo
27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, ...
Posted by Michael Wonder on 25 Aug 2021
NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer
25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or ...
Posted by Michael Wonder on 20 Aug 2021
NICE draft guidance extends recommendation for sapropterin to pregnant women and people aged up to 22 years with rare inherited metabolic condition phenylketonuria
20 August 2021 - NICE has today issued final draft guidance which now recommends sapropterin (Kuvan; BioMarin) as an option for ...
Posted by Michael Wonder on 19 Aug 2021
NICE’s health technology assessment methods and processes to be evaluated
19 August 2021 - NICE has launched a public consultation on proposed changes to the way it develops recommendations across ...
Posted by Michael Wonder on 19 Aug 2021
NICE recommends first treatment for rare blood disorder
19 August 2021 - People with a rare blood disorder have access to a new treatment following draft guidance from NICE. ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 18 Aug 2021
MS drug: Hull couple's treatment denied by 'cruel' postcode lottery
18 August 2021 - A couple who both have multiple sclerosis say they are being denied a drug which could ...
Posted by Michael Wonder on 18 Aug 2021
Abiraterone acetate for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer
18 August 2021 - NICE has published final guidance on the use of Zytiga in newly diagnosed patients following an ...
Posted by Michael Wonder on 12 Aug 2021
NICE draft guidance recommends abemaciclib for advanced breast cancer
12 August 2021 - NICE has today published draft guidance which recommends a twice daily pill abemaciclib (Verzenios; Eli Lilly) as ...
Posted by Michael Wonder on 10 Aug 2021
‘Life-changing’ MS drug costs £600 a month in England but is free on NHS in Scotland
9 August 2021 - Multiple sclerosis patients in England are paying £600 a month for a “life-changing drug” which is ...
Posted by Michael Wonder on 05 Aug 2021
Pfizer epilepsy drug prices were 'unfairly high,' UK review finds
5 August 2021 - Britain's competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law ...
Posted by Michael Wonder on 04 Aug 2021
How to balance the patient voice atop the shifting plates of HTA
3 August 2021 - The tectonic plates of healthcare technology assessment have shifted – but where does the patient voice ...
Posted by Michael Wonder on 02 Aug 2021
NICE approves first treatment in pilot of new approach to cost comparison fast track appraisals
2 August 2021 - As part of the recovery from the COVID-19 pandemic, NICE has been working hard to find new ...
Posted by Michael Wonder on 02 Aug 2021
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis
2 August 2021 - NICE has issued a Final Appraisal Determination recommending UCB’s bimekizumab as an option for the treatment ...